<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902380</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0644</org_study_id>
    <nct_id>NCT02902380</nct_id>
  </id_info>
  <brief_title>The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical stress induces stress hormone release and sympathetic hyperactivation.
      Dexmedetomidine has sympatholytic effect and attenuates stress responses. This study
      investigate the effect of dexmedetomidine on stress responses and autonomic nervous system
      balance in patients undergoing major spine surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stress hormone level</measure>
    <time_frame>immediately after anesthetic induction</time_frame>
    <description>The levels of stress hormone including epinephrine, norepinephrine, cortisol, and glucose will be measured during spinal surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress hormone level</measure>
    <time_frame>1 hour after start of surgery</time_frame>
    <description>The levels of stress hormone including epinephrine, norepinephrine, cortisol, and glucose will be measured during spinal surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress hormone level</measure>
    <time_frame>2-hour after start of surgery</time_frame>
    <description>The levels of stress hormone including epinephrine, norepinephrine, cortisol, and glucose will be measured during spinal surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress hormone level</measure>
    <time_frame>1 second after the end of surgery</time_frame>
    <description>The levels of stress hormone including epinephrine, norepinephrine, cortisol, and glucose will be measured during spinal surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress hormone level</measure>
    <time_frame>1 hour after the end of surgery</time_frame>
    <description>The levels of stress hormone including epinephrine, norepinephrine, cortisol, and glucose will be measured during spinal surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine group</intervention_name>
    <description>dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery</description>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>0.9% saline infusion</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ

          -  patient scheduled for major spine surgery

        Exclusion Criteria:

          -  ASA physical status Ⅳ

          -  congestive heart failure

          -  severe hepatorenal disease

          -  insulin dependent DM(diabetes mellitus)

          -  cancer or metastasis

          -  pregnancy

          -  problem with communication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-Sun Cho, MD</last_name>
    <phone>82-2-2227-0396</phone>
    <email>chjs0214@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Sun Cho, MD</last_name>
      <phone>82-2-2227-0396</phone>
      <email>chjs0214@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 11, 2016</lastchanged_date>
  <firstreceived_date>September 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
